AIM ImmunoTech said that it has extended a 2020 agreement with Shenzhen Smoore Technology related to development of an inhaled version of its Ampligen rintatolimod for the treatment of COVID-19. The agreement with Smoore is for the use of a Smoore-designed “personal inhalation device designed to administer Ampligen, given temperature parameters of dsRNA.” According to AIM, an inhalation safety study is expected to begin before the end of 2021.
AIM is also developing an intranasal formulation of Ampligen and initiated a Phase 1 safety study of the nasal spray in March 2021. The company previously announced positive interim results from the Phase 1 nasal spray study and has now announced additional results.
AIM CEO Thomas K. Equels said, “With Smoore’s concept for an Ampligen inhalation delivery device ready to be developed, and Ampligen’s track record of both safety and efficacy, we believe AIM is well positioned to move forward with our goal of developing Ampligen as a potential inhalation therapy for COVID-19 and potentially other respiratory viral diseases. We are in the process of planning a Phase 1/2 inhalation clinical study on a parallel track with Smoore’s device development testing.”
Smoore Chief Scientist and Director of Global R&D Zhiqiang Shi commented, “Application of vaping technology in healthcare and pharmaceutical fields is one of our R&D focus. We are really happy to partner with AIM to explore applications of advanced atomization technology in medical inhalation therapy. We will coordinate our device development work along with our partner’s plan and the regulation needs to move into next phase testing on schedule.”
Read the AIM Immunotech press release about the Smoore deal extension.
Read the AIM Immunotech press release about the intranasal Ampligen study results.
